Pathway Studio® is a complete research informatics solution that integrates proprietary knowledge with findings from published literature in an analytical framework to reveal molecular connections that summarize the state of current knowledge and power novel discovery. To learn more visit: www.pathwaystudio.com
SwitchGear offers 12,000 pre-cloned 3'UTR luciferase reporter vectors for cell-based assays. Validate the targets of any miRNA quickly and easily with our full LightSwitch miRNA Target Validation System including 3’UTR reporters, controls, miRNA mimics and inhibitors, and luciferase assay reagents. Visit SwitchGear Genomics and explore our sets of genome-wide, assay-ready promoter and 3’UTR reporters.
Nature Reviews Drug Discovery is on Twitter
Advertisement
Nature Reviews Cancer & Nature Reviews Immunology FOCUS ON TUMOUR IMMUNOLOGY & IMMUNOTHERAPY Access the Focus online for FREE until end of September 2012: www.nature.com/reviews/focus/tumourimmunology
Drug-making plant blooms doi:10.1038/485160a Approval of a 'biologic' manufactured in plant cells may pave the way for similar products. Full Text
Stromedix acquisition signals growing interest in fibrosis doi:10.1038/nbt0512-375 A deal in which Biogen Idec purchased the startup Stromedix indicates growing optimism that better biological targets are being identified and addressed in the underserved indication of fibrosis. Full Text
Deal watch: Alcon invests in first non-surgical therapy for common eye disorder doi:10.1038/nrd3736 ThromboGenics has entered into a commercialization agreement with Alcon for its experimental therapeutic ocriplasmin, which has successfully completed Phase III trials for an eye disorder known as symptomatic vitreomacular adhesion. Full Text
Affymax poised to challenge Amgen doi:10.1038/nbt0512-377 The 20-year dominance of Amgen's erythropoietins in the US anemia market looks like it may be coming to an end. Full Text
Heart beats fat doi:10.1038/scibx.2012.455 The findings that knocking down microRNA-208a in the heart leads to systemic benefits in obesity and metabolic diseases could expand the potential indications for miRagen's antimiR-208, which is in preclinical development for cardiac hypertrophy. Full Text
Fresh from the Pipeline: Ivacaftor doi:10.1038/nrd3723 First disease-modifying drug approved in the United States for the treatment of cystic fibrosis in patients with a specific mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator. Full Text
From the analyst's couch: Drug development risk and the cost of capital doi:10.1038/nrd3722 This article analyses the relationship between risk and the cost of capital for projects in different stages of drug development and describes a framework that could improve portfolio optimization strategies. Full Text
Neurodegenerative disease: The stress of misfolding doi:10.1038/nrd3731 Two studies provide evidence that α-synuclein-induced endoplasmic reticulum (ER) stress has a crucial role in promoting neurodegeneration in α-synucleinopathies, and that targeting chronic ER stress may represent a plausible target for future therapies. Full Text
Cancer genomics: Constructing a 'cancerpaedia' doi:10.1038/nrd3730 Two recent papers published in Nature report on genomic changes in cancer cell lines that indicate sensitivity to targeted drugs. Full Text
Mouse models: Of mice and men doi:10.1038/nrc3270 A clinical trial in mice with lung cancer indicates the likely efficacy of the MEK inhibitor selumetinib in a current ongoing human clinical trial. Full Text
Epigenetic protein families: a new frontier for drug discovery doi:10.1038/nrd3674 In this article, the authors review the protein families that mediate epigenetic signalling through histone acetylation and methylation, and highlight progress in the pharmacological modulation of each class of proteins. Full Text
Intra-tumour heterogeneity: a looking glass for cancer? doi:10.1038/nrc3261 This Review outlines both genetic and non-genetic causes of phenotypic heterogeneity of tumour cells and the implications of intra-tumour heterogeneity in diagnostics and the development of therapeutic resistance. Full Text
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma doi:10.1038/nature11114 A transposon-mediated insertional mutagenesis screen reveals inactivation of the X-linked deubiquitinase gene Usp9x in over 50% of pancreatic ductal adenocarcinomas, suggesting Usp9x has prognostic and therapeutic relevance for this disease. Full Text
A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation doi:10.1038/nchembio.957 A chemoproteomic approach adapted for high-throughput screening leads to the identification of a selective PI3Kγ inhibitor. Application of this inhibitor in human and mouse cellular models reinforces selective inhibition of PI3Kγ as a potential treatment for inflammatory and autoimmune diseases. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment